A carregar...

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides and macrocycles (2015–2018)

INTRODUCTION: The protein protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs. More...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Expert Opin Ther Pat
Main Authors: Shaabani, Shabnam, Huizinga, Harmen P.S., Butera, Roberto, Kouchi, Ariana, Guzik, Katarzyna, Magiera-Mularz, Katarzyna, Holak, Tad A., Dömling, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6323140/
https://ncbi.nlm.nih.gov/pubmed/30107136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543776.2018.1512706
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!